243 related articles for article (PubMed ID: 32867595)
1. Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.
van Egmond N; Straub VM; van der Stelt M
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():441-463. PubMed ID: 32867595
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
4. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
5. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.
Hruba L; Seillier A; Zaki A; Cravatt BF; Lichtman AH; Giuffrida A; McMahon LR
J Pharmacol Exp Ther; 2015 May; 353(2):261-8. PubMed ID: 25711338
[TBL] [Abstract][Full Text] [Related]
7. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
Schlosburg JE; Carlson BL; Ramesh D; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
AAPS J; 2009 Jun; 11(2):342-52. PubMed ID: 19430909
[TBL] [Abstract][Full Text] [Related]
9. O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.
Niphakis MJ; Johnson DS; Ballard TE; Stiff C; Cravatt BF
ACS Chem Neurosci; 2012 May; 3(5):418-26. PubMed ID: 22860211
[TBL] [Abstract][Full Text] [Related]
10. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.
Panlilio LV; Thorndike EB; Nikas SP; Alapafuja SO; Bandiera T; Cravatt BF; Makriyannis A; Piomelli D; Goldberg SR; Justinova Z
Psychopharmacology (Berl); 2016 May; 233(10):1879-88. PubMed ID: 26558620
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.
Kinsey SG; Long JZ; Cravatt BF; Lichtman AH
J Pain; 2010 Dec; 11(12):1420-8. PubMed ID: 20554481
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge.
Nass SR; Long JZ; Schlosburg JE; Cravatt BF; Lichtman AH; Kinsey SG
J Neuroimmune Pharmacol; 2015 Jun; 10(2):364-70. PubMed ID: 25715681
[TBL] [Abstract][Full Text] [Related]
13. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
Aly E; Masocha W
IBRO Neurosci Rep; 2021 Jun; 10():109-118. PubMed ID: 34179865
[TBL] [Abstract][Full Text] [Related]
14. Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.
Wise LE; Long KA; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
ACS Chem Neurosci; 2012 May; 3(5):369-78. PubMed ID: 22860205
[TBL] [Abstract][Full Text] [Related]
15. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
17. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
De Petrocellis L; Ligresti A; Moriello AS; Allarà M; Bisogno T; Petrosino S; Stott CG; Di Marzo V
Br J Pharmacol; 2011 Aug; 163(7):1479-94. PubMed ID: 21175579
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.
Ghafouri N; Tiger G; Razdan RK; Mahadevan A; Pertwee RG; Martin BR; Fowler CJ
Br J Pharmacol; 2004 Nov; 143(6):774-84. PubMed ID: 15492019
[TBL] [Abstract][Full Text] [Related]
19. Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine.
Della Pietra A; Giniatullin R; Savinainen JR
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530477
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate.
Nallapaneni A; Liu J; Karanth S; Pope C
Neurotoxicology; 2008 Nov; 29(6):1037-43. PubMed ID: 18765251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
